Back to discover
Disease

Autoinflammation with pulmonary and cutaneous vasculitis

Late-stage therapeutic development
20
Clinical trials
3
Associated genes
1
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 6 clinical trials expected to report results, the earliest in Q1 2028.
Upcoming Milestones
Clinical Milestones6View
Results expected 5
Activity timeline6

Clinical trials

16 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
20
All trials
6
Active
13
Late-stage
6
Completed
Late-stage studies

A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet's Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis

Phase 3 · Recruiting · Amgen

Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS)

Phase 3 · Recruiting · AstraZeneca

Salvage Therapy for Patients With Inadequate Response to Standard of Care Therapy in Granulomatosis With Polyangiitis

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris

Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) Trial

Phase 3 · Recruiting · Ottawa Hospital Research Institute

A Multicenter, Single-arm/Randomized, Double-blind, Active-controlled, Parallel-group Phase 2/3 Clinical Study to Evaluate the Efficacy and Safety of SHR-1703 for Patients With EGPA

Phase 2/3 · Recruiting · Guangdong Hengrui Pharmaceutical Co., Ltd

The Assessment of Prednisone In Remission Trial (TAPIR) - Centers of Excellence Approach

Phase 3 · Completed · University of Pennsylvania
Recruiting

A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet's Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis

Phase 3 · Recruiting · Amgen

Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS)

Phase 3 · Recruiting · AstraZeneca

Salvage Therapy for Patients With Inadequate Response to Standard of Care Therapy in Granulomatosis With Polyangiitis

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris

Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) Trial

Phase 3 · Recruiting · Ottawa Hospital Research Institute

A Multicenter, Single-arm/Randomized, Double-blind, Active-controlled, Parallel-group Phase 2/3 Clinical Study to Evaluate the Efficacy and Safety of SHR-1703 for Patients With EGPA

Phase 2/3 · Recruiting · Guangdong Hengrui Pharmaceutical Co., Ltd
Recently completed

The Assessment of Prednisone In Remission Trial (TAPIR) - Centers of Excellence Approach

Phase 3 · Completed · University of Pennsylvania

MAINtenance of Remission With RITuximab Versus Azathioprine for Patients With Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Prospective, Randomized, Controlled, Double-blind Study: the MAINRITSEG Trial

Phase 3 · Completed · Assistance Publique - Hôpitaux de Paris

Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE)

Phase 3 · Completed · University of South Florida

Mepolizumab Long-term Access Programme for Subjects Who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard-of-care Therapy)

Phase 3 · Completed · GlaxoSmithKline

Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study

Phase 3 · Completed · Assistance Publique - Hôpitaux de Paris

A Phase III Study of Efficacy, Safety and Tolerability of Chronocort® Compared With Standard Glucocorticoid Replacement Therapy in the Treatment of Congenital Adrenal Hyperplasia

Phase 3 · Completed · Neurocrine UK Limited

Associated genes

3 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

HCK0.40NUDT190.05FAM124A0.04

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Tyrosine-protein kinase HCKvia HCK0.40
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.